Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) have earned an average recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $18.5833.

A number of brokerages recently weighed in on ATEC. Stifel Nicolaus decreased their price objective on shares of Alphatec from $24.00 to $20.00 and set a “buy” rating for the company in a research report on Monday, March 9th. HC Wainwright reissued a “buy” rating and issued a $24.00 price objective on shares of Alphatec in a research report on Thursday, May 7th. JPMorgan Chase & Co. decreased their price objective on shares of Alphatec from $24.00 to $16.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Wells Fargo & Company decreased their price objective on shares of Alphatec from $28.00 to $14.00 and set an “overweight” rating for the company in a research report on Thursday, May 7th. Finally, Canaccord Genuity Group decreased their price objective on shares of Alphatec from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th.

Alphatec Price Performance

Shares of NASDAQ ATEC opened at $7.66 on Wednesday. Alphatec has a 52-week low of $6.82 and a 52-week high of $23.29. The firm has a fifty day moving average of $10.76 and a 200-day moving average of $15.50. The stock has a market capitalization of $1.18 billion, a PE ratio of -9.34 and a beta of 0.96. The company has a quick ratio of 1.12, a current ratio of 1.90 and a debt-to-equity ratio of 40.35.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings data on Tuesday, May 5th. The medical technology company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.21). Alphatec had a negative net margin of 15.93% and a negative return on equity of 1,183.84%. The company had revenue of $192.11 million for the quarter, compared to analysts’ expectations of $197.51 million. During the same period in the prior year, the firm earned ($0.35) earnings per share. The firm’s quarterly revenue was up 13.6% on a year-over-year basis. On average, analysts anticipate that Alphatec will post -0.44 EPS for the current year.

Insider Activity at Alphatec

In other news, EVP David Sponsel sold 163,452 shares of the company’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $12.52, for a total value of $2,046,419.04. Following the sale, the executive vice president owned 504,932 shares in the company, valued at approximately $6,321,748.64. This represents a 24.45% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Craig E. Hunsaker sold 82,765 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $12.45, for a total transaction of $1,030,424.25. Following the completion of the sale, the executive vice president owned 1,726,209 shares in the company, valued at approximately $21,491,302.05. This trade represents a 4.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 629,189 shares of company stock worth $7,801,589. Company insiders own 13.48% of the company’s stock.

Institutional Investors Weigh In On Alphatec

Several institutional investors and hedge funds have recently bought and sold shares of the business. Quantinno Capital Management LP raised its stake in Alphatec by 34.4% during the first quarter. Quantinno Capital Management LP now owns 21,452 shares of the medical technology company’s stock worth $233,000 after acquiring an additional 5,487 shares during the period. Entropy Technologies LP raised its stake in Alphatec by 127.8% during the first quarter. Entropy Technologies LP now owns 28,685 shares of the medical technology company’s stock worth $312,000 after acquiring an additional 16,092 shares during the period. Renaissance Technologies LLC raised its stake in Alphatec by 21.3% during the first quarter. Renaissance Technologies LLC now owns 1,055,100 shares of the medical technology company’s stock worth $11,479,000 after acquiring an additional 184,969 shares during the period. Arrowstreet Capital Limited Partnership raised its stake in Alphatec by 102.3% during the first quarter. Arrowstreet Capital Limited Partnership now owns 507,017 shares of the medical technology company’s stock worth $5,516,000 after acquiring an additional 256,342 shares during the period. Finally, Sei Investments Co. raised its stake in Alphatec by 62.2% during the first quarter. Sei Investments Co. now owns 598,003 shares of the medical technology company’s stock worth $6,506,000 after acquiring an additional 229,238 shares during the period. Institutional investors and hedge funds own 66.35% of the company’s stock.

Alphatec News Roundup

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on Alphatec and reiterated a $24 price target, while still projecting long-term EPS improvement to $0.88 in FY2028 and $1.00 in FY2029. HC Wainwright estimates and rating update
• Neutral Sentiment: Analysts at HC Wainwright lowered near-term earnings estimates for Q2 2026 and Q3 2026, but also raised some longer-range forecasts, indicating a mixed outlook rather than a full shift in sentiment. HC Wainwright earnings estimate changes
• Neutral Sentiment: Multiple articles recapped that Alphatec was weaker after its latest earnings-related reaction, suggesting investors are still digesting the company’s recent operating performance and sector backdrop. Street reaction to Alphatec post earnings
• Negative Sentiment: Several law firms announced or promoted securities fraud investigations into Alphatec following its May 5 earnings release, which can weigh on investor confidence and raise overhang risk for the shares. Howard G. Smith securities investigation
• Negative Sentiment: Another note highlighted a price target cut to $18.95, reinforcing a more cautious near-term view from the market. Price target decreased to 18.95

Alphatec Company Profile

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.